ORIGINAL ARTICLESLong-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol
REFERENCES (24)
Improved delivery of inhaled steroids to the large and small airways
Respir Med
(1998)- et al.
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers
Int J Pharm
(1999) - et al.
Safety of hydrofluoroalkane −134a beclomethasone dipropionate extrafine aerosol
Respir Med
(1998) - et al.
Efficacy response of inhaled beclomethasone in asthma is proportional to dose and is improved by formulation with a new propellant
J Allergy Clin Immunol
(1999) - et al.
Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
Respir Med
(1998) - et al.
HFA-134a BDP, 400 μg, is as effective as CFC-BDP, 800 μg, for the treatment of moderate asthma
Chest
(1999) - et al.
Efficacy of CFC-free beclomethasone dipropionate 400 μg.day-1 delivered as an extrafine aerosol in adults with moderate asthma
Respir Med
(1998) - et al.
The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide
Neth J Med
(1997) The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP 1987)
Fed Reg
(1994)- et al.
Chlorofluorocarbon-free inhalers: are we ready for the change?
Eur Respir J
(1998)
New delivery systems and propellants
Can Respir J
A conceptual model for the development of pressurized metered-dose hydrofluoroalkane-based inhalation aerosols
Pharm Technol
Cited by (48)
Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients
2018, Journal of the Formosan Medical AssociationCitation Excerpt :The ICS dose was 2.5 folds lower in the BDP/F group (400 μg beclomethasone) than in the FP/S group (1000 μg BDP-equivalent). The smaller mass median aerodynamic diameter (MMAD) of BDP/F extrafine formulation14 improves the delivery of the medication to peripheral airways15 and increased the percentage of lung deposition,16 and thus, allows a lower dose than traditional chlorofluorocarbon BDP to achieve the same efficacy.17–20 With lower ICS dose in combination with formoterol, BDP/F showed similar efficacy and even more rapid onset of action in treating asthma as compared with FP/S.
Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma
2013, Respiratory MedicineCitation Excerpt :The lung deposition of extrafine beclometasone is much greater than that of CFC-beclometasone (55–60% compared with 4–7% for CFC-beclometasone in healthy volunteers) and oropharyngeal deposition is lower (29–30% versus 90–94%).4–6 When switched from CFC-beclometasone to extrafine beclometasone at half the dose, patients in short-term randomised controlled trials maintained similar degrees of asthma control, with comparable safety profile, while those in a 12-month pragmatic trial experienced significantly greater improvement in health-related quality of life and a significantly higher percentage of symptom-free days than patients maintained on CFC-beclometasone.7–12 Efficacy in randomised controlled trials, which study tightly defined populations outside the normal ecology of care, does not necessarily translate to effectiveness in a real-life clinical setting, where factors that can influence and interact with asthma-related outcomes include co-morbidities, polypharmacy, smoking habits, poor inhaler technique, and suboptimal adherence.13–16
Should fracture risk influence our decision making in asthma care?
2011, Annals of Allergy, Asthma and ImmunologyBeclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma
2007, Respiratory MedicineEvaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids
2007, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :The protein-binding fraction is not available for beclomethasone-17-monopropionate; however, its parent compound, beclomethasone dipropionate, is 87% protein bound.55 Although beclomethasone dipropionate HFA-MDI has been reported to have less systemic activity at approximately half the dose of that reported with beclomethasone dipropionate CFC-MDI (400-1,600 μg once daily),76 HPA axis suppression has been shown with beclomethasone dipropionate HFA-MDI at high doses (250-500 μg twice daily).77 For example, in a 6-week study of patients with mild to moderate asthma, beclomethasone dipropionate HFA-MDI (250-500 μg twice daily) caused significant (P < .05) suppression of overnight urinary cortisol (corrected for creatinine) levels vs baseline, with the higher dose also causing greater suppression compared with fluticasone propionate HFA-MDI (500 μg twice daily) (P < .05).77
The functional benefit of anti-inflammatory aerosols in the lung periphery
2006, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The absence of FEF25-75 change seen here when switching from DPI-BUD to HFA-BDP at full or half dose agrees with previous reports of similar FEF25-75 improvements in asymptomatic patients after either DPI-BUD or HFA-BDP at half dose.6,15 The improved functionality of the acinar lung zone was accompanied by significant but mild changes in FEV1, which is the parameter that is most frequently used to assess the status of patients with asthma when comparing efficacy of inhaled drugs.6,7,9,10-12 Several of these previous reports have studied patients with poorly controlled asthma (usually undertreated in terms of steroid dose) before switching them to either ultrafine HFA-BDP or a coarser inhaled steroid aerosol.6,7,9,10,12
This study was sponsored by 3M Pharmaceuticals.